What's in Life for a Child Program, Diabetes Australia's pipeline?

Life for a Child Program, Diabetes Australia has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Life for a Child Program, Diabetes Australia's portfolio?

Top competitors by shared drug class: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, Gan and Lee Pharmaceuticals, USA, Massachusetts General Hospital, Merck Sharp & Dohme LLC, Novo Nordisk A/S.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/life-for-a-child-program-diabetes-australia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Life for a Child Program, Diabetes Australia — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Life for a Child Program, Diabetes Australia pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
biosimilar insulin glargine	biosimilar insulin glargine	marketed	Long-acting basal insulin	Insulin receptor	Diabetes

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 shared drug class
Gan and Lee Pharmaceuticals, USA · 1 shared drug class
Massachusetts General Hospital · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Novo Nordisk A/S · 1 shared drug class
Providence Health & Services · 1 shared drug class
Rabin Medical Center · 1 shared drug class
Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Life for a Child Program, Diabetes Australia:

Cite this brief

Drug Landscape (2026). Life for a Child Program, Diabetes Australia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/life-for-a-child-program-diabetes-australia. Accessed 2026-05-16.